

DMD #18879

**Title page**

**The potential influence of CO<sub>2</sub>, as an agent for euthanasia, on the pharmacokinetics of basic compounds in rodents.**

Derek W Angus, James A Baker, Rona Mason and Iain J Martin

Department of Pharmacology, Organon Laboratories Ltd., Newhouse, Lanarkshire, ML1  
5SH, UK.

DMD #18879

## Running title page

a) Running title:

Influence of CO<sub>2</sub> on rodent PK

b) Corresponding author:

Dr Iain Martin

Organon Laboratories Ltd

Newhouse

ML1 5SH

UK

Email: [i.martin@organon.co.uk](mailto:i.martin@organon.co.uk)

Tel: +44 (0)1698 736315

Fax: +44 (0)1698 736336

|                              |      |
|------------------------------|------|
| c) Number of text pages:     | 14   |
| Number of tables:            | 3    |
| Number of figures:           | 6    |
| Number of references:        | 26   |
| Number of words in Abstract: | 188  |
| Introduction:                | 352  |
| Discussion:                  | 1332 |

d) List of nonstandard abbreviations:

DMD #18879

AUC, area under the drug concentration time curve; CD, cervical dislocation; CL, plasma clearance; CP, cardiac puncture; MeCN, acetonitrile; IS, internal standard;

$V_{ss}$ , steady state volume of distribution

DMD #18879

## Abstract

Rodent tissue distribution and pharmacokinetic studies were performed on basic compounds Org A and Org B in support of CNS drug discovery programs. A consistent observation from these studies was that drug concentrations in plasma obtained by cardiac puncture after CO<sub>2</sub> euthanasia were markedly higher compared to other sampling methods (serial sampling, isoflurane anaesthesia or cervical dislocation). Further investigations demonstrated that CO<sub>2</sub> euthanasia led to a reduction in blood pH in both rats and mice which was not observed with the other sampling methods. The use of CO<sub>2</sub> euthanasia resulted in a decrease in the brain:plasma ratio of Org B, largely as a result of increased plasma concentrations. The pharmacokinetics of a basic drug, raloxifene, in rat were also influenced by sampling technique. CO<sub>2</sub> euthanasia prior to sampling, resulted in a 2-3 fold increase in AUC, decrease in CL and decrease in steady state volume of distribution compared to isoflurane anaesthesia. It is proposed that a decrease in the pH of blood relative to that of other tissues, as a consequence of CO<sub>2</sub> exposure, results in a redistribution of basic compounds out of the tissues, leading to higher concentrations in plasma.

## Introduction

For tissue distribution studies or combined tissue distribution/pharmacokinetic studies in rodents, a common approach is to administer test compound to several groups of animals. Subsequently, at each designated timepoint, blood and tissue samples are taken from a group of animals following euthanasia. A survey of the literature indicates that various methods of euthanasia are used for these types of studies including CO<sub>2</sub> inhalation (Sauer et al., 1997; Doran et al., 2005; Becker and Liu, 2006; Venkatakrishnan et al., 2007), pentobarbital (Groll et al., 2005; Washington et al., 2000), isofluorane (Gustafson et al., 2006), halothane (Hepburn et al., 2001) and decapitation (Hong et al., 2006). In many cases the method of euthanasia was not reported.

At Organon, various CNS discovery programs have entailed the study of the pharmacokinetics and brain distribution of drug candidates in both mice and rats. Until recently, the typical sampling design of these studies in our laboratory had been as follows. For rat pharmacokinetic studies, serial blood samples were taken from a tail vein with a terminal sample taken by Cardiac Puncture (CP) following CO<sub>2</sub> euthanasia. For rat and mouse brain distribution studies and mouse pharmacokinetic studies, groups of animals were sacrificed at various timepoints (CO<sub>2</sub>) prior to blood sampling (CP) and tissue harvesting.

Data from several unconnected studies in our laboratory suggested that, for some basic compounds, the different methods of sample collection (CP versus tail vein)

DMD #18879

resulted in differences in the observed drug concentration in plasma. Whilst the dependence of drug concentration on sampling site is well-established (Chiou, 1989) this could not adequately explain all of the observations. An alternative hypothesis was that the use of CO<sub>2</sub> prior to blood sampling resulted in alteration of physiological pH giving rise to changes in compound distribution and hence changes in plasma concentrations. Further studies were performed with the aim of investigating this hypothesis. Data was generated on 2 proprietary small molecules (Org A and Org B) as well as raloxifene (Evista<sup>TM</sup>); all three compounds are basic with pKa 9.48, 9.69 and 7.33 respectively. The initial observations and the results of these follow-up studies will be described and discussed.

## Materials and Methods

**Materials.** Raloxifene was obtained from Sigma-Aldrich (Poole, UK). Org A and Org B were synthesised at Organon Laboratories Ltd. (Newhouse, UK). Solvents and other reagents were obtained from common sources and were of reagent grade or better. For oral administration, Org A (1mg/ml) was suspended with 0.5% (v/v) gelatin in 5% (v/v) mannitol. Org B (1 mg/ml) was dissolved in isotonic saline for both oral and intravenous administration. Raloxifene (1 mg/ml) was suspended in 5% (v/v) mulgofen in isotonic saline for oral administration and dissolved in 10% (v/v) dimethyl acetamide in water for intravenous administration.

**Animals.** Male Wistar BRL rats (200-300 g) and male mice (ICR or MF1, 20-30 g; Harlan, Bicester, UK) were maintained on a 12-h light/dark cycle in a temperature- and humidity-controlled room with access to water and food *ad libitum*. All procedures involving animals were governed by a Project licence granted by the UK Home Office under the Animals (Scientific Procedures) Act 1986.

**Plasma pharmacokinetics.** Animals were administered with test compound either orally or intravenously and blood samples collected at predetermined timepoints. Dose levels were as indicated in the appropriate tables and figures. For rat studies, blood samples were taken from either a lateral tail vein or from an indwelling jugular vein or carotid artery cannula. For mouse studies, blood samples were taken by CP.

**Multiple sampling site studies.** Rats were administered orally with test compound (Org A, 10 mg/kg; Org B, 5 mg/kg). At 4 h post-dose, blood samples were obtained from a lateral tail vein and an indwelling carotid artery cannula. Following euthanasia by overexposure to CO<sub>2</sub>, further blood samples were collected from each of the heart (CP), jugular vein, trunk and thoracic artery.

**Termination method studies.** Three groups of mice (ICR, n=8) were administered orally with Org A (10 mg/kg). At 1 h post-dose blood (CP) and brain samples were collected from each group following euthanasia by either cervical dislocation (CD) or CO<sub>2</sub> inhalation or following anaesthesia by isofluorane.

**Blood gas analysis.** Rats or mice (ICR), were sacrificed by one of 3 methods: (a) CD, (b) CO<sub>2</sub> inhalation or (c) isofluorane anaesthesia followed by CD. A blood sample was obtained by CP from each animal and assayed using a blood gas analyser (ABL500, Radiometer Ltd., Crawley, UK) to obtain blood pH and pCO<sub>2</sub>.

**Sample preparation and LC/MS/MS analysis.** All blood samples were centrifuged (4000 x g for 10 min at 4°C) to obtain plasma. Brains were collected into ice-cold phosphate buffered saline (pH 7.4), rinsed with a further aliquot of the same buffer, blotted dry on filter paper (Whatman, Maidstone, UK) and weighed. Plasma and brain samples were stored at -20°C prior to analysis by HPLC-MS/MS. Samples were quantified using either a PE-Sciex API-365 (turbo ionspray source, 300°C) or an API-



DMD #18879

3000 (turbo ionspray source, 300°C, PerkinElmerSciex Instruments, Boston, MA) quadruple mass spectrometer. Plasma samples (50 µl) were prepared for analysis by protein precipitation using 150 µl acetonitrile (MeCN) containing 100 ng/ml of an appropriate internal standard (IS). The samples were vortex-mixed, centrifuged (4000 x g for 10 min at 4°C) and an aliquot of supernatant removed for analysis. Prior to analysis, 100 µl water was added to each supernatant sample. Brain samples were homogenised after addition of 3 volumes of phosphate buffered saline. An aliquot (200 µl) of the homogenate was removed and protein was precipitated by addition of 600 µl MeCN containing IS. The samples were vortex-mixed and centrifuged (4000 x g for 10 min at 4°C) and an aliquot of supernatant removed for analysis. Prior to analysis, 250 µl water was added to each supernatant sample and each sample was analysed in triplicate. Samples were injected (10-50µl; CTC Analytics, Zwingen, Switzerland) onto a Phenomenex 50 x 2 mm, 5 µm Develosil C30 (Phenomenex, Macclesfield, UK) column at room temperature. The run time varied for each analyte (3.5 – 6 min). Raloxifene and Org A were eluted with a linear gradient consisting of 0.1% formic acid in water [“A”] and 0.1% formic acid in MeCN [“B”] produced by two binary pumps [raloxifene, Shimadzu LC-10ADVP (Shimadzu, Milton Keynes, UK); Org A, Perkin Elmer Series 200 micropumps (PerkinElmerSciex Instruments, Boston, MA, USA)]. Org B was eluted with a linear gradient consisting of ammonium formate in water (10 mM) [“A”] and MeOH [“B”] produced by two Shimadzu LC-10ADVP binary pumps (Shimadzu). For Org A, the initial condition was 100% “A” held for 1 min then ramped to 100% “B” over 3 min and held for 0.5 min. The initial condition was returned to over 0.5 min and then held for a further 1

DMD #18879

min. Org B conditions started at 90% “A” held for 1 min then ramped to 100% “B” over 0.5 min and held for 0.5 min then returned to initial conditions over 0.5 min and held for a further 1 min. Raloxifene initial conditions were 100% “A” held for 1 min then ramped to 100% “B” over 1 min and held for 1 min. Initial conditions were returned to over 0.1 min and held for 0.9 min. For all analytes, the flow rate was 1 ml/min. Standards, quality control and blank samples were prepared with either plasma or brain homogenate and were identical in composition to corresponding test samples. Accuracy of standards and quality control samples was within  $\pm 20\%$  of the nominal value. The MS/MS transitions were 497.3/126.3 (Org A), 272.1/110.25 (Org B) and 474.16/112.25 for raloxifene.

**Data analysis.** Data processing was performed using Excel (Microsoft, Redmond, WA, USA) and WinNonlin v5.0.1 (Pharsight, Mountain View, CA, USA). Statistical analyses were performed using Minitab release 14 (Minitab Inc., State College, PA, USA).

## Results

**Plasma pharmacokinetic studies.** Data from a brain penetration study and a pharmacokinetic study with Org A are shown in Figure 1. Plasma samples obtained by CP following CO<sub>2</sub> euthanasia gave consistently higher concentrations compared to those obtained by tail venepuncture. The estimated difference in AUC was approximately 3-fold although, due to differences in the design of the two studies, no statistical comparison was performed. Data from a pharmacology study with Org A, where the same rats were sampled by two methods, are given in Table 1. The plasma concentrations at 2 h following oral administration were between 2 and 3-fold greater in the CP samples compared to the jugular vein samples across a range of doses (3 – 30 mg/kg).

Following intravenous administration of Org B to rats, the plasma concentrations from samples taken at 24 h from the carotid artery were 2-3 fold lower than those from samples taken immediately afterwards (from the same animals) by CP after CO<sub>2</sub> euthanasia (Figure 2).

Following intravenous administration to male MF1 mice, plasma levels of raloxifene obtained following CO<sub>2</sub> euthanasia were consistently higher than those obtained following isoflurane anaesthesia (Figure 3). Estimated non-compartmental pharmacokinetic parameters (sparse analysis) with the CO<sub>2</sub> sampling method yielded

a higher AUC, lower CL and lower  $V_{ss}$  compared to the isoflurane technique (Table 2).

**Multiple sampling site studies.** Further studies with Org A and Org B in rats indicated that there was a difference in the plasma concentrations between samples obtained before and after CO<sub>2</sub> euthanasia from a variety of sampling sites. The trend of the mean data, shown in Figures 4 and 5 was also reflected in each individual animal (data not shown).

**Termination method studies.** The plasma and brain concentrations obtained 1 h following single oral administration of Org B to mice (10 mg/kg) are shown in Figure 6. Plasma concentrations from mice sacrificed by CD were similar to those obtained under isoflurane anaesthesia whereas the mice sacrificed by CO<sub>2</sub> euthanasia showed substantially higher concentrations. The brain concentrations of Org A appeared broadly similar between the three groups. Brain:plasma ratios derived from these data were 52.8, 45.4 and 23.5 for the CD, isoflurane and CO<sub>2</sub> groups respectively.

**Blood gas analysis studies.** In both rat and mouse, the pH of blood obtained following CO<sub>2</sub> euthanasia was markedly lower than that obtained by either CD or isoflurane (Table 3).

## Discussion

The plasma concentration-time profile for Org A (Figure 1) shows a clear difference between samples taken by CP following CO<sub>2</sub> euthanasia and those taken from a tail vein. Similar observations were made in a pharmacology study (Table 1) with the CP samples giving consistently higher concentrations of Org A than the jugular vein samples from the same animals. Sample site-dependent differences in drug levels have been discussed by Chiou (1989). For drugs which distribute into tissues, marked differences in concentration between arterial and venous samples have been observed. In the early (distributional) phase following drug administration, venous concentrations can be much lower due to the net uptake of drug during its passage across the tissues. During the elimination phase, with decreasing arterial concentrations, drug will redistribute out of the tissues resulting in higher venous concentrations. Since the concentrations of Org A in the CP samples (Figure 1) are consistently higher than the venous samples throughout the study, it is not clear that the phenomena discussed by Chiou (1989) could be responsible for the observations, although a more complete profile may have aided interpretation. Further, from the imprecise nature of CP sampling, it is not possible to say whether this represents arterial blood, venous blood or a mixture. Differences in plasma concentration between sampling methods were also observed during a study of the pharmacokinetics of Org B in rats (Figure 2). Concentrations of Org B were appreciably higher in a CP sample (CO<sub>2</sub> euthanasia) taken from the same animals

DMD #18879

immediately after a carotid artery sample. This observation is not inconsistent with sample site-dependent differences (Chiou, 1989).

To investigate these initial observations further, the concentrations of Org A and Org B from various sampling sites were studied after oral administration to rats (Figures 4 and 5). For both compounds, concentrations from various sampling sites (both arterial and venous) taken after CO<sub>2</sub> euthanasia were higher than those taken prior to CO<sub>2</sub> euthanasia. It was thought that the carotid artery and thoracic artery samples would not be susceptible to sample site differences and that a statistical comparison would therefore be justified. The thoracic artery concentrations (post CO<sub>2</sub>) were significantly higher than the carotid artery samples (pre-CO<sub>2</sub>) for both Org A (4.7-fold) and Org B (3.3-fold). This suggested that other factors aside from sample site and arteriovenous differences were responsible for the observations.

Lipophilic basic drugs are characterised by high volumes of distribution as a consequence of extensive uptake into tissues. The mechanisms governing tissue uptake are thought to be an interplay between phospholipid binding and ion-trapping (Romer and Bickel, 1979; MacIntyre and Cutler, 1988; Hung et al., 2002; Siebert et al., 2004). Ion trapping occurs as a consequence of the pH differences between blood, tissues and subcellular organelles, especially lysosomes, which are maintained at a pH range of 4-5 (de Duve et al., 1974). For basic drugs, a greater proportion of the drug will exist in the protonated form in lower pH environments. Since the protonated form is considered unable (or only sparingly able) to cross biological

DMD #18879

membranes, the net result is a sequestration of drug into compartments of lower pH. Clearly then, a change in the pH of blood, tissues or lysosomes has the potential to alter the distribution characteristics of an ionisable drug as has been reported in several laboratories (Lüllmann et al., 1985; Shibasaki, 1989; Ishizaki et al., 1998). Indeed, modulation of distribution via alterations in pH has been proposed as a means of enhancing the efficacy of anticancer drugs (reviewed by Kaufmann and Krise, 2007).

In the current study, euthanasia of rats and mice with CO<sub>2</sub> resulted in markedly lower blood pH (Table 3) as a consequence of an increase in blood pCO<sub>2</sub> (data not shown). Changes in arterial blood and tissue intracellular pH in rats, in response to CO<sub>2</sub> inhalation, has previously been reported by Rothe (1984). In arterial blood, the fall in pH was approximately twice that observed in liver, spleen and heart muscle whereas skeletal muscle pH appeared resistant to mild acidosis. In contrast, changes in brain pH were quantitatively similar to arterial blood (Rothe, 1984). In the current study, anaesthesia with isoflurane did not appear to affect blood pH as compared to the CD group. Although isoflurane has been reported to produce acidosis in mice (Sjöblom and Nylander, 2007), this was relatively mild (blood pH 7.15) and took 2 hours to develop. Therefore a possible explanation for the higher plasma levels of Org A and Org B after CO<sub>2</sub> euthanasia is that the fall in blood pH, relative to tissues, results in redistribution of compound out of the tissues and acidic organelles into the blood. In a brain distribution study with Org A in mice (Figure 6), plasma levels were higher in the CO<sub>2</sub> euthanasia group compared to the isoflurane and CD groups. Brain tissue

DMD #18879

levels of Org A were slightly lower in the CO<sub>2</sub> group although this was not statistically significant. As a consequence mainly of the increased plasma concentration, the brain:plasma ratio of Org A derived from the CO<sub>2</sub> group (23.5) was around 2-fold lower compared to the isoflurane (45.4) and cervical dislocation (52.8) groups. It is possible that a relatively small redistribution from multiple tissues could lead to a marked increase in plasma concentrations. Whilst brain:plasma ratios give a useful indication of the distributional properties of a drug, CSF drug levels are the preferred means, in our laboratory, of assessing CNS exposure with respect to pharmacological effect (Martin, 2004) and extrapolation to man. It would therefore be of interest to study the influence of CO<sub>2</sub> on drug levels in CSF in relation to plasma.

A study of the pharmacokinetics of raloxifene in mice after intravenous administration provided further evidence of the influence of CO<sub>2</sub>. The plasma levels of raloxifene obtained after CO<sub>2</sub> euthanasia were consistently higher than those obtained under isoflurane anaesthesia (Figure 3) and yielded a 2-fold higher AUC ( $p < 0.001$ ). This difference was reflected in the estimated CL and V<sub>ss</sub> (Table 2). Again, it is suggested that exposure to CO<sub>2</sub> immediately prior to sampling, and the concomitant fall in blood pH, resulted in a redistribution of this basic compound out of the tissues leading to higher observed plasma levels.

A series of observations from unconnected studies and subsequent follow-up investigations has provided evidence that different methods of blood sample



collection can lead to differences in the data obtained. The results of these investigations led us to suspect that the use of CO<sub>2</sub> euthanasia in tissue distribution and pharmacokinetic studies on basic compounds could yield potentially artefactual plasma concentration data. We are aware of several literature reports where CO<sub>2</sub> euthanasia has also been employed during tissue distribution or pharmacokinetic studies on other basic compounds (Handal et al., 2002; Debruyne et al., 2003; Polli et al., 2003; Meririnne et al., 2004; Doran et al., 2005; Liu et al., 2006; Venkatakrishnan et al., 2007). In one of these reports (Meririnne et al., 2004), rat tissue samples were obtained following decapitation under light sedation with CO<sub>2</sub>. It was stated that preliminary tests demonstrated that tissue concentrations (including blood and brain) of 4-methylaminorex were not affected by light exposure to CO<sub>2</sub>. Since these data were not reported it is difficult to make comparisons with data obtained in the current study (Figure 6) and assess the possible difference between light sedation and euthanasia. Nonetheless, the results presented here suggest that a re-evaluation of data generated from studies employing CO<sub>2</sub> anaesthesia or euthanasia may be warranted. Further studies would be required to clarify the mechanisms responsible for the observations described in this paper including investigating the effect of CO<sub>2</sub> on pH and drug distribution in various tissues. Studies on compounds with a wider range of basic pKa's and lipophilicities as well as acidic compounds are also indicated. Although not thought to be relevant to the compounds in the present study, the potential influence of CO<sub>2</sub> on reversible metabolism should be considered in future work of this type. The data presented here have prompted a change to isoflurane anaesthesia in our laboratory.

DMD #18879

## **Acknowledgments**

The authors would like to acknowledge the assistance of members of the Department of Pharmacology, Organon Laboratories Ltd., Newhouse in carrying out this work.

DMD #18879

## References

Becker S and Liu X (2006) Evaluation of the utility of brain slice methods to study brain penetration. *Drug Metab Dispos* **34**: 855-861.

Chiou WL (1989) The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I). *Clin Pharmacokinet* **17**:175-199.

Debruyne D, Sobrio F, Hinschberger A, Camsonne R, Coquerel A and Barre L (2003) Short-term pharmacokinetics and brain distribution of mecamlamine as a preliminary to carbon-11 labeling for nicotinic receptor investigation. *J Pharm Sci* **92**:1051-1057.

de Duve C, de Barse T, Poole B, Trouet A, Tulkens P and Van Hoof F (1974) Lysosomotropic agents. *Biochem Pharmacol* **23**:2495-2531.

Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfroga J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS and Zhang C (2005) The impact of P-glycoprotein on the disposition of drugs targeted for

DMD #18879

indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. *Drug Metab Dispos* **33**:165-174.

Groll AH, Mickiene D, Petraitis V, Petraitiene R, Kelaher A, Sarafandi A, Wuerthwein G, Bacher J and Walsh TJ (2005) Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits. *J Antimicrob Chemoth* **56**:899-907.

Gustafson DL, Bradshaw-Pierce EL, Merz AL and Zirrolli JA (2006) Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing. *J Pharmacol Exp Ther* **318**:872-880.

Hong Z, Fan G, Le J, Chai Y, Yin X and Wu Y (2006) Brain pharmacokinetics and tissue distribution of tetrahydropalmatine enantiomers in rats after oral administration of the racemate. *Biopharm Drug Dispos* **27**:111-117.

Handal M, Grung M, Skurtveit S, Ripel A and Morland J (2002) Pharmacokinetic differences of morphine and morphine-glucuronides are reflected in locomotor activity. *Pharmacol Biochem Behav* **73**:883-892.

Hung DY, Chang P, Cheung K, McWhinney B, Masci PP, Weiss M and Roberts MS (2002) Cationic drug pharmacokinetics in diseased livers determined by fibrosis index,

DMD #18879

hepatic protein content, microsomal activity, and nature of drug. *J Pharmacol Exp Ther* **301**:1079-1087.

Ishizaki J, Yokogawa K, Nakashima E, Ohkuma S and Ichimura F (1998) Influence of ammonium chloride on the tissue distribution of anticholinergic drugs in rats. *J Pharm Pharmacol* **50**:761-766.

Kaufmann AM and Krise JP (2007) Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. *J Pharm Sci* **96**:729-746.

Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA and Van Deusen J (2006) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. *Drug Metab Dispos* **34**:1443-1447.

Lullmann H, Martins B-S and Peters T (1985) pH-dependent accumulation of fentanyl, lofentanil and alfentanil by beating guinea pig atria. *Br J Anaes* **57**:1012-1017.

MacIntyre AC and Cutler DJ (1988) The potential role of lysosomes in tissue distribution of weak bases. *Biopharm Drug Dispos* **9**:513-526.

Martin IJ (2004) Prediction of blood-brain barrier penetration: are we missing the point? *Drug Discov Today* **9**:161-162.

DMD #18879

Meririnne E, Ellermaa S, Kankaanpaa A, Bardy A and Seppala T (2004)

Pharmacokinetics and tissue distribution of the stereoisomers of 4-methylaminorex in the rat. *J Pharmacol Exp Ther* **309**:1198-1205.

Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Salisbury JA, Tippin TK and Serabjit-Singh CJ (2003). P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. *J Pharm Sci* **92**:2082-2089.

Romer J and Bickel MH (1979) Interactions of chlorpromazine and imipramine with artificial membranes investigated by equilibrium dialysis, dual-wavelength photometry, and fluorimetry. *Biochem Pharmacol* **28**:799-805.

Rothe KF (1984) Effect of respiratory and non-respiratory (metabolic) changes of extracellular pH value on intracellular pH value of various rat tissues in vivo. Relations between extra- and intracellular acid-base balance in clinically normal and extreme ranges. I. *Anesthesie, Intensivtherapie, Notfallmedizin* **19**:184-190.

Sauer JM, Bao J, Smith RL, Kuester RK, Mayersohn M and Sipes IG (1997) Absorption, disposition, and metabolism of trans-methyl styryl ketone in female B6C3F1 mice. *Drug Metab Dispos* **25**:1184-1190.

DMD #18879

Shibasaki S, Kawamata Y, Nishigaki R and Umemura K (1989) Effects of cimetidine on quinidine distribution and tissue pH in rats. *J Pharmacobio-Dyn* **12**:324-331.

Siebert GA, Hung DY, Chang P and Roberts MS (2004) Ion-trapping, microsomal binding and unbound drug distribution in the hepatic retention of basic drugs. *J Pharmacol Exp Ther* **308**:228-235.

Sjöblom M and Nylander O (2007). Isoflurane-induced acidosis depresses basal and PGE(2)-stimulated duodenal bicarbonate secretion in mice. *Am J Physiol*, **292**:G899-904.

Venkatakrishnan K, Tseng E, Nelson FR, Rollema H, French JL, Kaplan IV, Horner WE and Gibbs MA (2007) CNS Pharmacokinetics of the MDR1 P-glycoprotein substrate CP-615,003: Inter-site differences and implications for human receptor occupancy projections from CSF exposures. *Drug Metab Dispos* **35**:1341-1349.

Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L and Blaschke TF (2000) The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. *Drug Metab Dispos* **28**:1058-1062.

DMD #18879

### **Footnotes**

Send reprint requests to:

Dr Iain Martin

Organon Laboratories Ltd

Newhouse

Motherwell

ML1 5SH

Email: [i.martin@organon.co.uk](mailto:i.martin@organon.co.uk)



DMD #18879

## Legends for figures

Figure 1.

Plasma concentrations of Org A following single oral administration to male Wistar BRL rats (10 mg/kg). Open symbols represent samples taken by tail venepuncture (serial sampling, mean  $\pm$  SD, n=4) and closed symbols represent samples taken by CP following CO<sub>2</sub> euthanasia (terminal sampling, mean  $\pm$  SD, n=4 at each timepoint).

Figure 2.

Plasma concentrations of Org B following single intravenous administration to male Wistar BRL rats (3 mg/kg, mean  $\pm$  SD, n=3). Open symbols represent samples taken from the carotid artery and the closed symbol represents a sample taken by CP following CO<sub>2</sub> euthanasia. \*Statistically different from carotid artery sample  $p < 0.05$  by one-sample t-test.

Figure 3.

Plasma concentrations of raloxifene following single intravenous administration to male MF1 mice (1 mg/kg, mean  $\pm$  SD, n=4 per timepoint). Open symbols represent samples taken under isoflurane anaesthesia and closed symbols represent samples taken following CO<sub>2</sub> euthanasia.

DMD #18879

Figure 4.

Plasma concentrations of Org A from various sampling sites at 4h after single oral administration to male Wistar BRL rats (10 mg/kg, mean  $\pm$  SD, n=4). Samples were taken either pre- (shaded bars: TV tail vein; CA carotid artery) or post- (open bars: CP cardiac puncture; JV jugular vein; TR trunk; TA thoracic artery) CO<sub>2</sub> euthanasia. \*Statistically different from CA, p<0.05, one-sample t-test.

Figure 5.

Plasma concentrations of Org B from various sampling sites at 4h after single oral administration to male Wistar BRL rats (5 mg/kg, mean  $\pm$  SD, n=4). Samples were taken either pre- (shaded bars: TV tail vein; CA carotid artery) or post- (open bars: CP cardiac puncture; JV jugular vein; TR trunk; TA thoracic artery) CO<sub>2</sub> euthanasia. \*Statistically different from CA, p<0.05, one-sample t-test.

Figure 6.

Mean ( $\pm$  SD) concentrations of Org B in male ICR mouse plasma (open bars) and brain (shaded bars) at 1 h after single oral administration (10 mg/kg). Samples obtained following euthanasia by either CO<sub>2</sub> inhalation (n=8) or CD (n=5) or under isofluorane anaesthesia (n=8). \*p<0.01 compared to CD or isofluorane group (Analysis of variance, Tukey's method).

DMD #18879

## Tables

Table 1. Plasma concentrations of Org A at 2 h following single oral administration to male Sprague Dawley rats (mean  $\pm$  SD, n=4) at various dose levels.

| Dose (mg/kg) | Plasma concentration (ng/ml)            |                      |
|--------------|---|----------------------|
|              | CP following CO <sub>2</sub> euthanasia | Jugular vein cannula |
| 3            | 202 $\pm$ 106**                         | 66 $\pm$ 18          |
| 5            | 437 $\pm$ 151***                        | 143 $\pm$ 53         |
| 10           | 866 $\pm$ 163***                        | 437 $\pm$ 75         |
| 30           | 3346 $\pm$ 979***                       | 1640 $\pm$ 335       |

Statistically different from jugular vein group by one-sample t-test; \*\*p<0.01, \*\*\*p<0.001

DMD #18879

Table 2. Non-compartmental pharmacokinetic parameters of raloxifene estimated following single intravenous administration to male MF1 mice (1 mg/kg, n=4 per timepoint). Samples were taken by CP after either CO<sub>2</sub> euthanasia or isoflurane anaesthesia.

|  | Sampling method               |                |
|--|-------------------------------|----------------|
|  | CO <sub>2</sub>               | Isoflurane     |
| AUC <sub>0-7.5 h</sub> (ng.h/ml); (95% confidence intervals) | 334 <sup>***</sup> (317, 351) | 161 (147, 176) |
| CL (ml/min/kg)   | 49                            | 98             |
| V <sub>ss</sub> (l/kg)                                       | 2.7                           | 9.0            |

\*\*\* Statistically different from Isoflurane, p<0.001 ; z-test following sparse analysis in WinNonlin

DMD #18879

Table 3. pH and gas composition of mouse and rat blood taken by CP following either CO<sub>2</sub> euthanasia, isoflurane anaesthesia or cervical dislocation (CD; mean ± SD).

|    | Mouse                      |             |                | Rat                        |             |             |
|----|----------------------------|-------------|----------------|----------------------------|-------------|-------------|
|    | CO <sub>2</sub>            | Isoflurane  | CD             | CO <sub>2</sub>            | Isoflurane  | CD          |
| n  | 8                          | 7           | 2 <sup>¶</sup> | 8                          | 8           | 8           |
| pH | 6.74 ± 0.03 <sup>†††</sup> | 7.23 ± 0.08 | 7.19           | 6.68 ± 0.11 <sup>***</sup> | 7.32 ± 0.04 | 7.39 ± 0.13 |

¶ due to technical difficulties

Significantly different from both isoflurane and CD groups (\*\*\*, p<0.001) or isoflurane group (†††, p<0.001); analysis of variance, Tukey's method.

Figure 1






Figure 2



Downloaded from dmd.aspetjournals.org at ASPET Journals on April 23, 2022


Figure 3



Downloaded from dnd.aspetjournals.org at ASPET Journals on April 23, 2024




Figure 4



Downloaded from dnd.aspetjournals.org at ASPET Journals on April 23, 2024

Figure 5



Downloaded from dnd.aspejournals.org at ASPET Journals on April 23, 2024

Figure 6

